V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20130514 | 20134249 | 1.61 | 97.2 | Curative (C) | null | 2019-09-08 | Carboplatin + Liposomal Doxorubicin | N | N | PACLITAXEL + RAMUCIRUMAB | 101856671 |
| 20130606 | 20134250 | 1.6 | 113.5 | 03 | 2017-04-20 | 2017-05-10 | NAB PACLITAXEL | N | null | RITUXIMAB | 101804728 |
| 20130639 | 20134251 | 1.54 | 62 | Curative (C) | 2018-12-19 | 2019-01-27 | Cyclophosphamide Weekly PO | N | null | CYCLOPHOSPHAMIDE | 100312151 |
| 20130640 | 20134252 | 1.72 | 38.7 | Palliative (P) | 2017-04-12 | 2017-04-28 | Docetaxel + nintedanib | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101565384 |
| 20130681 | 20134253 | 1.83 | 80 | Curative (C) | 2019-12-13 | 2019-12-27 | Bevacizumab + FLUOROURACIL + IRINOTECAN | N | N | CAPECITABINE + LOMUSTINE | 100098582 |
| 20130723 | 20134254 | 1.91 | null | Neo-adjuvant (N) | null | 2017-11-07 | Methotrexate intrathecal | N | Y | AZACITIDINE | 101603228 |
| 20130762 | 20134255 | 0 | 0 | Palliative (P) | 2017-01-31 | 2017-01-31 | FOXTROT TRIAL | N | N | DARATUMUMAB | 100789923 |
| 20130859 | 20134256 | 1.58 | 78 | Curative (C) | 2021-06-30 | 2021-11-10 | Amsacrine + FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100969867 |
| 20131277 | 20134258 | 1.8 | 58 | Curative (C) | 2017-06-09 | 2017-06-29 | COSMIC TRIAL | 99 | N | CARBOPLATIN + VINORELBINE | 100068975 |
| 20131500 | 20134259 | 1.56 | 80.4 | Palliative (P) | 2020-02-14 | 2020-02-14 | SCOPE 2 TRIAL | N | N | CYCLOPHOSPHAMIDE + METHOTREXATE | 100071965 |
| 20131657 | 20134260 | 1.72 | 82 | null | 2021-12-10 | 2022-01-29 | Topotecan (oral) | N | Y | TCX | 100573187 |
| 20131694 | 20134261 | 1.69 | 21.2 | Neo-adjuvant (N) | 2020-02-03 | 2020-02-05 | Cetuximab + Irinotecan (Cycle 1) | N | N | PALBOCICLIB | 101227084 |
| 20131724 | 20134262 | 1.89 | 53 | Palliative (P) | 2016-10-03 | 2016-10-14 | SCOPE 2 TRIAL | 02 | N | CHLORAMBUCIL + OBINUTUZUMAB | 100383634 |
| 20131833 | 20134263 | 1.61 | 67.8 | null | 2018-08-03 | 2018-08-06 | TRANSPLANT BEAM | 02 | N | CEDAR TRIAL | 100567027 |
| 20131845 | 20134264 | null | 62 | Adjuvant (A) | 2016-05-16 | 2016-07-26 | Capecitabine+Trastuzumab 21dayMaint | 2 | N | BORTEZOMIB + THALIDOMIDE | 101408031 |
| 20131904 | 20134266 | 1.65 | 66.75 | Palliative (P) | 2017-05-21 | 2017-07-24 | Bortezomib + MELPHALAN | N | N | CISPLATIN + IFOSFAMIDE + MITOMYCIN | 100112547 |
| 20131959 | 20134267 | 1.7 | 52 | Palliative (P) | 2018-09-21 | 2019-04-27 | ESPAC-4 TRIAL | N | N | RITUXIMAB + VENETOCLAX | 101090541 |
| 20132255 | 20134269 | 1.75 | 84.4 | Palliative (P) | 2017-10-02 | 2017-10-11 | Topotecan (oral) | N | N | CAP + RT | 101091159 |
| 20132270 | 20134270 | 1.56 | 63.25 | Palliative (P) | 2020-02-04 | 2020-02-04 | AML 19 TRIAL | N | null | IRINOTECAN + RALTITREXED | 101458958 |
| 20132504 | 20134272 | 1.75 | 68.35 | Palliative (P) | 2016-03-16 | 2016-04-21 | Durvalumab | N | N | PHITT D SIOPEL-4 (A1, A2, A3) | 101336593 |
| 20132554 | 20134274 | 1.56 | 90 | Palliative (P) | 2019-11-30 | 2019-11-30 | Triple Intrathecal | N | null | GO2 TRIAL | 100882584 |
| 20132589 | 20134275 | 1.55 | 71.6 | Palliative (P) | 2016-06-09 | 2016-06-24 | Ripretinib | 02 | N | TOPOTECAN | 101612757 |
| 20132615 | 20134276 | 1.77 | 64.2 | null | null | 2020-06-18 | ECF | null | null | PERTUZUMAB + TRASTUZUMAB | 101410148 |
| 20132689 | 20134277 | 1.49 | 60.4 | Palliative (P) | 2018-02-02 | 2018-02-23 | Durvalumab | 02 | N | ARISTOTLE TRIAL | 100298501 |
| 20132768 | 20134278 | 1.8 | 59.05 | null | 2019-03-19 | 2019-03-19 | Cabazitaxel | 02 | null | BRIGATINIB | 100870828 |
| 20133011 | 20134279 | 1.58 | 76.3 | Palliative (P) | 2020-12-28 | 2021-01-15 | AVELUMAB + AXITINIB | 02 | N | DARATUMUMAB | 100230205 |
| 20133069 | 20134280 | 1.71 | 94.4 | null | 2020-03-29 | 2020-05-31 | PHITT D SIOPEL-4 (A1, A2, A3) | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100072128 |
| 20133073 | 20134281 | 1.8 | 88 | Palliative (P) | 2016-05-20 | 2016-05-23 | Bortezomib + CYCLOPHOSPHAMIDE | N | Y | GEMCITABINE + PACLITAXEL | 100460249 |
| 20133166 | 20134282 | 1.72 | null | 03 | 2019-02-20 | 2019-03-02 | Triple Intrathecal | 02 | N | TOPOTECAN | 101471080 |
| 20133496 | 20134283 | 1.58 | 70.2 | Curative (C) | 2019-06-16 | 2019-07-07 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | null | EPIRUBICIN | 100415174 |
| 20133841 | 20134285 | 1.56 | 100 | Palliative (P) | 2017-01-02 | 2017-12-01 | Docetaxel+Gemcitabine (no prior RT) | 02 | null | IBRUTINIB | 100088563 |
| 20133853 | 20134286 | 1.92 | 59.8 | null | 2017-11-08 | 2018-04-02 | Letrozole + Palbociclib | 02 | null | GEMCARBO | 100014493 |
| 20134283 | 20134288 | 1.86 | 71 | null | 2019-11-02 | 2019-11-10 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | IPILIMUMAB + NIVOLUMAB | 101408901 |
| 20134721 | 20134290 | 1.5 | 65.7 | Palliative (P) | 2018-11-02 | 2019-03-01 | CAPECITABINE + MITOMYCIN + RT | 02 | null | CAPECITABINE + TRASTUZUMAB | 100284389 |
| 20134770 | 20134291 | 0.7 | 46.9 | Curative (C) | 2018-07-01 | 2018-07-07 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101506005 |
| 20134840 | 20134292 | 1.76 | 80 | Palliative (P) | 2019-09-28 | 2019-09-28 | CISPLATIN + TEYSUNO | null | N | DERAZANTINIB | 100714938 |
| 20134872 | 20134293 | 1.53 | 54.7 | null | 2016-04-27 | 2016-05-05 | ECarboX | 02 | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 101696186 |
| 20135005 | 20134294 | 1.65 | 91.8 | Adjuvant (A) | 2021-02-27 | 2021-02-28 | CHOP R | 02 | N | IBRUTINIB | 101151596 |
| 20135121 | 20134295 | 1.8 | 80.3 | null | 2018-03-04 | 2018-03-10 | EOF | 02 | null | CAPECITABINE + CARBOPLATIN + RT | 101133199 |
| 20135185 | 20134296 | 1.65 | 103.6 | Curative (C) | null | 2021-08-06 | CEMIPLIMAB | 01 | N | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101110654 |
| 20135389 | 20134297 | 0 | 0 | 03 | 2020-09-25 | 2021-08-29 | Atezolizumab | 02 | N | CISPLATIN + FLUOROURACIL + RT | 101563665 |
| 20135442 | 20134298 | 1.79 | 94.9 | Palliative (P) | 2018-05-29 | 2018-05-29 | null | 02 | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 101724864 |
| 20135459 | 20134299 | 1.65 | 15.5 | Neo-adjuvant (N) | 2019-01-30 | 2019-01-30 | ARISTOTLE TRIAL | 2 | Y | STAR TRIAL | 101253577 |
| 20135959 | 20134300 | 1.65 | 48 | Palliative (P) | 2021-03-10 | 2022-03-11 | CHOP R - 21 days | 02 | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100290402 |
| 20136217 | 20134301 | 1.8 | null | Palliative (P) | 2019-09-02 | 2019-09-02 | DOXORUBICIN | 2 | null | ABEMACICLIB + FULVESTRANT | 100015026 |
| 20136351 | 20134302 | 1.57 | 97 | Palliative (P) | 2019-10-19 | 2019-10-19 | Capecitabine + Docetaxel | 02 | null | FCARBOST | 100060612 |
| 20136372 | 20134303 | 1.82 | 47 | Palliative (P) | 2019-06-29 | 2020-02-06 | Liposomal Doxorubicin (Caelyx) | 02 | N | BEVACIZUMAB + IRINOTECAN + MdG | 100360565 |
| 20136470 | 20134304 | 1.8 | 70 | null | 2017-09-06 | 2017-09-16 | Durvalumab | 02 | null | CARBOPLATIN + PEMETREXED | 101538515 |
| 20136480 | 20134305 | 1.65 | 111 | Curative (C) | 2018-08-25 | 2018-08-26 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100018406 |
| 20136481 | 20134306 | 1.57 | 0 | null | 2016-12-27 | 2016-12-27 | Topotecan (oral) | 02 | null | AZACITIDINE | 100512315 |